Literature DB >> 203233

Minimal breast cancer: a clinical appraisal.

T G Peters, W L Donegan, E A Burg.   

Abstract

Eighty-five patients with a diagnosis of minimal breast cancer were evaluated. The predominant lesion was intraductal carcinoma, and axillary metastases occurred in association with minimal breast cancer in seven of 96 cases. One death occurred due to minimal breast cancer. Bilateral mammary carcinoma was evident in 24% and bilateral minimal breast cancer in 13% of the patients. The component lesions of minimal breast cancer have varied biologic activity, but prognosis is good with a variety of operations. The multifocal nature of minimal breast cancer and the potential for metastases should be recognized. Therapy should include removal of the entire mammary parenchyma and low axillary nodes. The high incidence of bilateral malignancy supports elective contralateral biopsy at the time of therapy for minimal breast cancer.

Entities:  

Mesh:

Year:  1977        PMID: 203233      PMCID: PMC1396506          DOI: 10.1097/00000658-197712000-00007

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  17 in total

1.  Intraductal carcinoma of the breast. A comparative study.

Authors:  K C Westbrook; H S Gallager
Journal:  Am J Surg       Date:  1975-12       Impact factor: 2.565

2.  Implications of suspicious findings in breast cancer screening.

Authors:  J D Lewis; J R Milbrath; K A Shaffer; T K Das Gupta
Journal:  Arch Surg       Date:  1975-08

3.  Lobular carcinoma of the breast in situ. Are we too radical in its treatment?

Authors:  C A Dall'Olmo; J L Ponka; R C Horn; R Riu
Journal:  Arch Surg       Date:  1975-05

4.  Lobular carcinoma--an indication for elective biopsy of the second breast.

Authors:  W L Donegan; C M Perez-Mesa
Journal:  Ann Surg       Date:  1972-08       Impact factor: 12.969

5.  Intraductal carcinoma of the breast. (1960-1969).

Authors:  R Ashikari; S I Hajdu; G F Robbins
Journal:  Cancer       Date:  1971-11       Impact factor: 6.860

6.  Epithelial-stromal junction of intraductal carcinoma of the breast.

Authors:  L Ozzello; P Sanpitak
Journal:  Cancer       Date:  1970-12       Impact factor: 6.860

7.  Current concepts in the detection and treatment of the earliest of the early breast cancers.

Authors:  J H Farrow
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

8.  Early phases in the development of breast cancer.

Authors:  H S Gallager; J E Martin
Journal:  Cancer       Date:  1969-12       Impact factor: 6.860

9.  On the diagnosis of minimal breast cancer in a screenee population.

Authors:  M Moskowitz; S Pemmaraju; J A Fidler; D J Sutorius; P Russell; P Scheinok; J Holle
Journal:  Cancer       Date:  1976-05       Impact factor: 6.860

10.  Intraductal "noninfiltrating" carcinoma of the breast.

Authors:  P W Brown; J Silverman; E Owens; D C Tabor; J J Terz; W Lawrence
Journal:  Arch Surg       Date:  1976-10
View more
  5 in total

1.  The role of mammography in the detection of bilateral primary breast cancer.

Authors:  J G Tinnemans; T Wobbes; J H Hendriks; R Holland; R F Van der Sluis; H H De Boer
Journal:  World J Surg       Date:  1988-06       Impact factor: 3.352

2.  Nuclear polymorphism--a prognostic parameter to evaluate local recurrence of female breast cancer.

Authors:  H R Rosen; M Stierer; R Weber
Journal:  Breast Cancer Res Treat       Date:  1990-11       Impact factor: 4.872

3.  Treatment and survival of female patients with nonpalpable breast carcinoma.

Authors:  J G Tinnemans; T Wobbes; R Holland; J H Hendriks; R F Van der Sluis; H H De Boer
Journal:  Ann Surg       Date:  1989-02       Impact factor: 12.969

4.  Engineering Lactococcus lactis for D-Lactic Acid Production from Starch.

Authors:  Yuji Aso; Ayaka Hashimoto; Hitomi Ohara
Journal:  Curr Microbiol       Date:  2019-07-13       Impact factor: 2.188

Review 5.  Management of in situ and minimally invasive breast carcinoma.

Authors:  E R Frykberg; K I Bland
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.